Sanofi is a drug manufacturers-general business based in the US. Sanofi stocks (SNY.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $51.42 – a decrease of 1.87% over the previous week. Sanofi employs 99,412 staff and has a trailing 12-month revenue of around $36.9 billion.
Since the stock market crash in March caused by coronavirus, Sanofi's stock price has had significant positive movement.
Its last market close was $52.43, which is 3.01% up on its pre-crash value of $50.85 and 39.37% up on the lowest point reached during the March crash when the stocks fell as low as $37.62.
If you had bought $1,000 worth of Sanofi stocks at the start of February 2020, those stocks would have been worth $797.24 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,083.73.
|Latest market close||$52.43|
|52-week range||$43.131 - $54.26|
|50-day moving average||$52.4163|
|200-day moving average||$50.3138|
|Wall St. target price||$65|
|Dividend yield||$3.2 (6.21%)|
|Earnings per share (TTM)||$5.7025|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 month (2021-06-25)||-0.91%|
|3 months (2021-04-26)||1.08%|
Valuing Sanofi stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Sanofi stocks trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.
Sanofi's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.1072. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Sanofi's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$10.6 billion.
The EBITDA is a measure of a Sanofi's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$36.9 billion|
|Operating margin TTM||21.1%|
|Gross profit TTM||USD$25.3 billion|
|Return on assets TTM||4.19%|
|Return on equity TTM||20.01%|
|Market capitalisation||USD$128.8 billion|
TTM: trailing 12 months
There are currently 5.0 million Sanofi stocks held short by investors – that's known as Sanofi's "short interest". This figure is 3.7% up from 4.8 million last month.
There are a few different ways that this level of interest in shorting Sanofi stocks can be evaluated.
Sanofi's "short interest ratio" (SIR) is the quantity of Sanofi stocks currently shorted divided by the average quantity of Sanofi stocks traded daily (recently around 1.5 million). Sanofi's SIR currently stands at 3.36. In other words for every 100,000 Sanofi stocks traded daily on the market, roughly 3360 stocks are currently held short.
However Sanofi's short interest can also be evaluated against the total number of Sanofi stocks, or, against the total number of tradable Sanofi stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sanofi's short interest could be expressed as 0% of the outstanding stocks (for every 100,000 Sanofi stocks in existence, roughly 0 stocks are currently held short) or 0.0022% of the tradable stocks (for every 100,000 tradable Sanofi stocks, roughly 2 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Sanofi.
Find out more about how you can short Sanofi stock.
Dividend payout ratio: 53.97% of net profits
Recently Sanofi has paid out, on average, around 53.97% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.75% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi shareholders could enjoy a 3.75% return on their shares, in the form of dividend payments. In Sanofi's case, that would currently equate to about $3.2 per share.
Sanofi's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Sanofi's most recent dividend payout was on 26 May 2021. The latest dividend was paid out to all shareholders who bought their stocks by 3 May 2021 (the "ex-dividend date").
Sanofi stocks were split on a 5:1 basis on 30 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi stocks – just the quantity. However, indirectly, the new 80% lower stock price could have impacted the market appetite for Sanofi stocks which in turn could have impacted Sanofi's stock price.
Over the last 12 months, Sanofi's stocks have ranged in value from as little as $43.131 up to $54.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi's is 0.4028. This would suggest that Sanofi's stocks are less volatile than average (for this exchange).
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Everything we know about the Ryan Specialty Group Holdings IPO, plus information on how to buy in.
Everything we know about the Ocean Biomedical IPO, plus information on how to buy in.
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
Everything we know about the Gambling.com Group IPO, plus information on how to buy in.
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
Everything we know about the Cytek Biosciences IPO, plus information on how to buy in.
Everything we know about the Core & Main IPO, plus information on how to buy in.
Everything we know about the Caribou Bioscience IPO, plus information on how to buy in.
Everything we know about the Candel Therapeutics IPO, plus information on how to buy in.
Everything we know about the Absci Corporation IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.